Drug interactions between Latisse and unoprostone ophthalmic
| Results for the following 2 drugs: |
|---|
| Latisse (bimatoprost topical) |
| unoprostone ophthalmic |
Interactions between your selected drugs
unoprostone ↔ bimatoprost
Applies to:unoprostone ophthalmic and Latisse (bimatoprost topical)
Consumer information for this interaction is not currently available.
MONITOR: In patients using bimatoprost or other prostaglandin analogs for the treatment of intraocular hypertension, the concomitant use of bimatoprost 0.03% ophthalmic solution to treat hypotrichosis of the eyelashes may interfere with the desired reduction in intraocular pressure (IOP). In clinical trials, bimatoprost 0.03% solution applied topically to the upper eyelid margin lowered IOP in both patients with or without elevated IOP, although the magnitude of the reduction was not cause for clinical concern. In previous studies of bimatoprost for the treatment of ocular hypertension, it has been shown that exposure of the eye to more than one dose of bimatoprost daily may decrease the IOP-lowering effect. Therefore, topical administration of bimatoprost to the eyelid in conjunction with ocular instillation of IOP-lowering prostaglandin analogs may decrease the IOP-lowering effect in ocular hypertensive patients.
MANAGEMENT: Patients using these products concomitantly should be closely monitored for changes to their intraocular pressure.
See also...
Drug Interaction Classification
The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2013 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
